Chemclin Diagnostics Co., Ltd. (SHA:688468)

Market Cap	2.86B -2.8%
Revenue (ttm)	332.68M -23.7%
Net Income	43.91M -65.4%
EPS	0.11 -65.6%
Shares Out	394.59M
PE Ratio	65.82
Forward PE	n/a
Dividend	0.13 (1.71%)
Ex-Dividend Date	Jun 13, 2025

Volume	4,947,727
Average Volume	2,907,887
Open	7.20
Previous Close	7.24
Day's Range	7.18 - 7.49
52-Week Range	6.76 - 9.12
Beta	0.13
RSI	46.99
Earnings Date	Apr 29, 2026

About Chemclin Diagnostics

Chemclin Diagnostics Co., Ltd. engages in the research and development, production, and sale of clinical immune chemiluminescence diagnostic reagents and instruments. Its products include LiCAA series of diagnostic reagents based on photo-induced chemiluminescence and CC series based on enzymatic chemiluminescence diagnostic reagents and instruments, primarily used for infectious diseases, such as hepatitis B, hepatitis C, AIDS, syphilis, hepatitis A, hepatitis E, etc.; and detection of tumor markers, thyroid hormones, reproductive endocrine ho...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2007
• Employees: 606
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688468

Financial Performance

In 2025, Chemclin Diagnostics's revenue was 332.68 million, a decrease of -23.75% compared to the previous year's 436.29 million. Earnings were 43.91 million, a decrease of -65.44%.